Nasdaq IPOs

Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, raised $230 million by offering 11.5 million shares at $20, above the upwardly revised range of $18 to $19. The company offered 1 million more shares than anticipated. It originally planned

Vor Biopharma, a preclinical biotech developing cell therapies for hematological diseases, raised $177 million by offering 9.8 million shares at $18, the high end of the range of $16 to $18. The company offered 1 million more shares than anticipated. At pricing, Vor Biopharma com

Sustainable Development Acquisition I, a blank check public benefit corporation formed by RRG and Capricorn Investment Group, raised $275 million by offering 27.5 million units at $10. The company offered 2.5 million more units than anticipated. Each unit consists of one sha

Ark Global Acquisition, a blank check company led by a former Groupon CEO and QIA fund manager targeting disruptive technology, raised $300 million by offering 30 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one share of c

Fifth Wall Acquisition I, a blank check company targeting a real estate technology business, raised $300 million by offering 30 million shares at $10. The company did not offer units with warrants attached. The company is led by CEO and Chairman Brendan Wallace, who ha

Thunder Bridge Capital Partners III, the third blank check company led by Gary Simanson targeting the fintech industry, raised $360 million by offering 36 million units at $10. The company offered 6 million more units than anticipated. Each unit consists of one share of comm

Compute Health Acquisition, a blank check company targeting the intersection of computation and healthcare, raised $750 million by offering 75 million units at $10. Each unit consists of one share of common stock and one-fourth of a warrant, exercisable at $11.50. Medical de

G Squared Ascend I, a blank check company formed by G Squared targeting the tech sector, raised $300 million by offering 30 million units at $10.The company offered 5 million more units than anticipated. Each unit consists of one share of common stock and one-fifth of a warrant,

JOFF Fintech Acquisition, a blank check company targeting the financial services industry and FinTech, raised $360 million by offering 36 million units at $10. The company offered 6 million more units than anticipated. Each unit consists of one share of common stock and one-

RMG Acquisition III, the third blank check company formed by Riverside's James Carpenter and former Carlyle executive Robert Mancini, raised $420 million by offering 42 million units at $10. Each unit consists of one share of common stock and one-fifth of a warrant, exercisa

Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company previously planned to offer 7.8 million shares. At $17, Lucira command

Pharvaris, a Phase 1 biotech developing oral small molecule therapies for rare diseases, raised $165 million by offering 8.3 million shares at $20, above the range of $17 to $19. The company sold 19% more shares than originally anticipated. The Netherlands-based biotech, which h

Immunocore Holdings, a Phase 3 biotech developing T cell therapies for cancer and other diseases, raised $258 million by offering 9.9 million ADSs at $26, above the range of $23 to $25. The company offered 19% more ADSs than anticipated at $26 based on an F-1MEF filing late Thurs

Immunocore Holdings, a Phase 3 biotech developing T cell therapies for cancer and other diseases, raised $258 million by offering 9.9 million ADSs at $26, above the range of $23 to $25. The company offered 19% more ADSs than anticipated at $26 based on an F-1MEF filing late Thurs

Altimar Acquisition II, the second blank check company formed by HPS Investment Partners, raised $300 million by offering 30 million units at $10. Each unit consists of one share of common stock and one-fourth of a warrant, exercisable at $11.50.  The company is led by

Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, raised $128 million by offering 7.5 million shares at $17, the high end of the range of $15 to $17. The company offered 1.3 million more shares than anticipated. At pricing, Terns commands a fu

Hudson Executive Investment III, the third blank company formed by Hudson Executive Capital targeting high-growth industries, filed on Thursday with the SEC to raise up to $500 million in an initial public offering. The New York, NY-based company plans to raise $500 million by o

BOA Acquisition, a blank check company targeting real estate technology, filed on Thursday with the SEC to raise up to $175 million in an initial public offering. The Washington, DC-based company plans to raise $175 million by offering 17.5 million units at $10. Each unit will c

KKR Acquisition Holdings I, a blank check company formed by KKR and former Gap CEO Glenn Murphy targeting the consumer sector, filed on Thursday with the SEC to raise up to $1.0 billion in an initial public offering. The New York, NY-based company plans to raise $1.0 billion by

ArcLight Clean Transition II, the second blank check company formed by ArcLight Capital Partners targeting renewables, filed on Thursday with the SEC to raise up to $250 million in an initial public offering. The Boston, MA-based company plans to raise $250 million by offering 2